Scarica l'app Stockscreener
220.37
1.82%
-4.09
Dopo l'orario di chiusura:
220.37
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RMD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$224.46
Aprire:
$222.68
Volume 24 ore:
1.45M
Relative Volume:
0.97
Capitalizzazione di mercato:
$31.79B
Reddito:
$5.54B
Utile/perdita netta:
$1.52B
Rapporto P/E:
21.24
EPS:
10.3734
Flusso di cassa netto:
$1.74B
1 W Prestazione:
+0.15%
1M Prestazione:
+10.74%
6M Prestazione:
-13.86%
1 anno Prestazione:
-22.65%
Intervallo 1D:
$218.66
$223.94
Intervallo di 1 settimana:
$215.71
$228.55
Portata 52W:
$180.26
$293.81
Resmed Inc Stock (RMD) Company Profile
Nome
Resmed Inc
Settore
Industria
Telefono
(858) 746-2400
Indirizzo
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD vs ISRG, BDX, ALC, MDLN
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
220.37 | 32.38B | 5.54B | 1.52B | 1.74B | 10.37 |
ISRG
Intuitive Surgical Inc
|
390.33 | 139.37B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
182.09 | 49.96B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
72.49 | 35.89B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
34.88 | 31.36B | 29.14B | 1.07B | 1.05B | 1.1956 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-15 | Iniziato | JP Morgan | Overweight |
| 2025-12-16 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2025-09-18 | Iniziato | Citigroup | Buy |
| 2025-09-02 | Aggiornamento | CLSA | Hold → Outperform |
| 2025-07-15 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-19 | Iniziato | Morgan Stanley | Overweight |
| 2025-01-16 | Iniziato | Goldman | Buy |
| 2025-01-10 | Iniziato | Piper Sandler | Neutral |
| 2024-12-13 | Iniziato | Stifel | Hold |
| 2024-09-24 | Iniziato | Robert W. Baird | Outperform |
| 2024-09-18 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | Downgrade | Needham | Buy → Hold |
| 2024-06-25 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-06-24 | Downgrade | Citigroup | Buy → Neutral |
| 2024-02-06 | Ripresa | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-09-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | Aggiornamento | Needham | Hold → Buy |
| 2023-09-05 | Downgrade | UBS | Buy → Neutral |
| 2023-08-01 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | Iniziato | UBS | Buy |
| 2023-04-14 | Iniziato | Mizuho | Buy |
| 2023-01-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-28 | Downgrade | Citigroup | Buy → Neutral |
| 2022-10-20 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-09-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-08-15 | Downgrade | CLSA | Buy → Outperform |
| 2022-08-12 | Downgrade | Citigroup | Buy → Neutral |
| 2022-08-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-08-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | Iniziato | Wolfe Research | Outperform |
| 2022-01-31 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-01-31 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-01-28 | Aggiornamento | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-01-13 | Aggiornamento | CLSA | Outperform → Buy |
| 2022-01-13 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | Aggiornamento | Macquarie | Neutral → Outperform |
| 2021-10-22 | Aggiornamento | CLSA | Underperform → Outperform |
| 2021-08-02 | Downgrade | CLSA | Outperform → Sell |
| 2021-08-02 | Downgrade | Needham | Buy → Hold |
| 2021-07-28 | Aggiornamento | Jefferies | Underperform → Hold |
| 2021-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-07-14 | Iniziato | RBC Capital Mkts | Underperform |
| 2021-06-28 | Downgrade | Citigroup | Buy → Neutral |
| 2021-06-22 | Aggiornamento | Macquarie | Neutral → Outperform |
| 2021-06-22 | Iniziato | Robert W. Baird | Neutral |
| 2021-06-21 | Reiterato | Needham | Buy |
| 2021-06-16 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-06-09 | Aggiornamento | CLSA | Sell → Outperform |
| 2021-05-21 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-04-30 | Downgrade | Citigroup | Buy → Neutral |
| 2021-03-16 | Aggiornamento | Needham | Hold → Buy |
| 2020-11-02 | Aggiornamento | UBS | Neutral → Buy |
| 2020-10-30 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2020-10-27 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2020-08-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | Downgrade | JP Morgan | Neutral → Underweight |
| 2020-05-01 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-02-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | Iniziato | CLSA | Underperform |
| 2020-01-31 | Downgrade | UBS | Buy → Neutral |
| 2020-01-10 | Iniziato | Oppenheimer | Perform |
| 2019-11-22 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | Aggiornamento | UBS | Neutral → Buy |
| 2019-07-16 | Downgrade | UBS | Buy → Neutral |
| 2019-05-06 | Aggiornamento | UBS | Neutral → Buy |
| 2019-04-18 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2019-01-25 | Downgrade | Goldman | Buy → Neutral |
| 2019-01-25 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-10-26 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | Iniziato | Goldman | Buy |
Mostra tutto
Resmed Inc Borsa (RMD) Ultime notizie
ResMed names Carol Burt as lead director, Ron Taylor to retire - Investing.com Canada
Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor - The Globe and Mail
A lead director's 21-year Resmed tenure is set to end in November - Stock Titan
ResMed’s (RMD) Sleep Business Booms Even As One Product Stumbles - Yahoo Finance
Could Cochlear (ASX:COH) and ResMed (ASX:RMD) Shape the Next Chapter? - Kalkine Media
87,722 Shares in ResMed Inc. $RMD Purchased by Avalon Trust Co - MarketBeat
41,381 Shares in ResMed Inc. $RMD Acquired by ABN AMRO Bank N.V. - MarketBeat
Why You Should Consider Buying ResMed Stock After Its First-Ever Annual Guide - TIKR.com
The 5 Most Interesting Analyst Questions From ResMed’s Q2 Earnings Call - Yahoo Finance
ResMed Inc. stock falls Friday, underperforms market - MarketWatch
ResMed Inc.: Financial Data Forecasts Estimates and Expectations | RMEA | AU000000RMD6 - marketscreener.com
ResMed, Inc.: Financial Data Forecasts Estimates and Expectations | RME | US7611521078 - marketscreener.com
ResMed (ASX:RMD) Keeps Dividend Momentum Going: Keep It on Your Radar - Kalkine
ResMed to sell MatrixCare business for $490 million - Minichart
ResMed Inc. Submits Annual 10-K Report for Fiscal Year Ending June 30, 2026 - Kalkine Media
ResMed Inc. Files Annual Form 10-K Report for Fiscal Year Ended June 30, 2026 - Kalkine
ResMed Submits 2026 Fiscal Year-End 10-K Annual Report Detailing Financial and Operational Metrics - Kalkine Media
RESMED INC. : RBC RAISES TARGET PRICE TO $244 FROM $234 - webull.com
RESMED INC FY 2026: Revenue $5.65B, EPS $10.43— 10-K Summary - TradingView
How Investors May Respond To ResMed (RMD) Dividend Hike And Ventilator Recall Headwinds - simplywall.st
Handelsbanken Fonder AB Raises Stock Position in ResMed Inc. $RMD - MarketBeat
Weekly Earnings Wrap: CBA, REA Group, Westpac, Resmed and more - Morningstar Australia
ResMed Inc. Stock 12‑Month Price Target Cut to $258.47, Implies 14% Upside - TradingView
ResMed Inc. (RMD) Stock Forecasts - Yahoo Finance
ResMed (RMD) Stock May Be 31% Undervalued After Soft FY27 Outlook - Yahoo Finance
ASX healthcare share remains cheap despite mixed earnings result - Morningstar Australia
Is Recall-Hit Outlook and Bigger Payout Altering The Investment Case For ResMed (RMD)? - Yahoo Finance
ResMed Chairman and CEO Michael Farrell Sells 4,991 Shares Under 10b5-1 Plan - Kalkine
ResMed Inc. stock rises Tuesday, outperforms market - MarketWatch
ResMed CEO Michael Farrell sells $1.03m in company stock By Investing.com - Investing.com India
Insider Selling: ResMed (NYSE:RMD) CEO Sells $1,026,598.79 in Stock - MarketBeat
ResMed CEO Michael Farrell sells $1.03m in company stock - Investing.com
Resmed Insider Sold Shares Worth $1,026,596, According to a Recent SEC Filing - marketscreener.com
Assenagon Asset Management S.A. Grows Stock Holdings in ResMed Inc. $RMD - MarketBeat
ResMed Bull Thinks Five-Year Outlook Is Intact -- Market Talk - Moomoo
Ord Minnett Remains a Buy on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) - The Globe and Mail
Macquarie Keeps Their Buy Rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) - The Globe and Mail
Citi Sticks to Their Hold Rating for Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) - The Globe and Mail
Is It Too Late to Buy ResMed Inc (RMD) After 3.8% Rally? GF Value Says Undervalued - GuruFocus
ResMed Inc. stock rises Monday, outperforms market - MarketWatch
ResMed’s Margin Squeeze and Astral Recall Overshadow Product Rollout and $1.5 Billion Buyback Plan - finance.biggo.com
Operating margin % of ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh – HAM:RMEA - TradingView
ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh - TradingView
Resmed Inc Stock (RMD) Moved Up by 3.01% on Aug 10: Key Drivers Unveiled - TradingKey
Resmed’s stock falls by 7% on soft FY27 outlook - Medical Device Network
ResMed Inc. (RMD) Stock Analysis: Unveiling a 16.64% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
ResMed: Result 2026 - intelligentinvestor.com.au
ResMed Price Target Raised 0.4% to A$46.80/Share by Macquarie - Moomoo
ResMed Inc. (NYSE:RMD) Just Reported Its Full-Year Results And Analysts Are Updating Their Forecasts - 富途牛牛
Here's What Analysts Are Forecasting For ResMed Inc. (NYSE:RMD) After Its Full-Year Results - simplywall.st
ResMed Q4 Earnings Call Highlights - Yahoo Finance
Resmed Inc Azioni (RMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.41%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):